Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

Phase 3

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: 5-Fluorouracil
Drug: Carboplatin
Drug: Cyclophosphamide
Drug: Docetaxel
Drug: Doxorubicin
Drug: Epirubicin
Drug: Paclitaxel
Drug: Placebo
Drug: Pertuzumab
Drug: Trastuzumab

First Posted Date: 2011-05-24

Last Posted Date: 2024-06-14

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 4804

Registration Number: NCT01358877

Locations: 🇺🇸
Texas Oncology - DFW, Dallas, Texas, United States
🇺🇸
The Mark H. Zangmeister Ctr; Mid Ohio Onc/Hem Inc., Columbus, Ohio, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 552 locations

A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: adavosertib
Drug: Placebo
Drug: paclitaxel
Drug: carboplatin

First Posted Date: 2011-05-20

Last Posted Date: 2023-09-21

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 136

Registration Number: NCT01357161

Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies

Phase 1

Completed

Conditions: Advanced Solid Malignancies
Hematologic Malignancies

Interventions: Drug: MLN0128
Drug: paclitaxel
Drug: trastuzumab

First Posted Date: 2011-05-10

Last Posted Date: 2019-08-08

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 68

Registration Number: NCT01351350

Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Not Applicable

Active, not recruiting

Conditions: Adenocarcinoma of the Lung
Adenosquamous Cell Lung Cancer
Large Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Squamous Cell Lung Cancer
Stage IIA Non-small Cell Lung Cancer
Stage IIB Non-small Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer

Interventions: Radiation: hypofractionated radiation therapy
Other: laboratory biomarker analysis
Radiation: image-guided radiation therapy
Drug: carboplatin
Drug: paclitaxel
Radiation: stereotactic body radiation therapy

First Posted Date: 2011-05-02

Last Posted Date: 2024-01-10

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 29

Registration Number: NCT01345851

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Indirect Comparison Topotecan Cervical Carcinoma

Completed

Conditions: Cervical Intraepithelial Neoplasia

Interventions: Drug: cisplatin
Drug: paclitaxel
Drug: topotecan

First Posted Date: 2011-05-02

Last Posted Date: 2017-05-30

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1

Registration Number: NCT01345279

Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery

Phase 1

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: carboplatin
Drug: RAD001
Drug: paclitaxel

First Posted Date: 2011-04-11

Last Posted Date: 2016-02-10

Lead Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group

Target Recruit Count: 49

Registration Number: NCT01333085

Locations: 🇫🇷
Hopital Beaujon, Clichy, France
🇫🇷
Centre Léon Berard, Lyon, France
🇫🇷
Institut Curie, Paris, France

and more 2 locations

PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy

Phase 2

Completed

Conditions: Adenocarcinoma of the Gastroesophageal Junction
Esophageal Cancer

Interventions: Drug: Oxaliplatin
Drug: Leucovorin Calcium
Drug: Fluorouracil
Drug: Carboplatin
Drug: Paclitaxel
Procedure: Positron Emission Tomography
Procedure: Computed Tomography
Radiation: Radiation Therapy

First Posted Date: 2011-04-11

Last Posted Date: 2023-04-13

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 257

Registration Number: NCT01333033

Locations: 🇺🇸
Diagnostic and Treatment Center, Weston, Wisconsin, United States
🇺🇸
Fletcher Allen Health Care - University Health Center Campus, Burlington, Vermont, United States
🇺🇸
Saint Joseph's Hospital, Marshfield, Wisconsin, United States

and more 65 locations

Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel

Phase 2

Completed

Conditions: Ovarian Cancer Recurrent

Interventions: Drug: Placebo
Drug: Ombrabulin (AVE8062)
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2011-04-11

Last Posted Date: 2015-12-21

Lead Sponsor: Sanofi

Target Recruit Count: 154

Registration Number: NCT01332656

Locations: 🇺🇸
Investigational Site Number 840002, Boston, Massachusetts, United States
🇨🇿
Investigational Site Number 203004, Zlin, Czech Republic
🇷🇺
Investigational Site Number 643003, Moscow, Russian Federation

and more 35 locations

A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: BBI608
Drug: Paclitaxel

First Posted Date: 2011-03-29

Last Posted Date: 2023-11-15

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 565

Registration Number: NCT01325441

Locations: 🇺🇸
Texas Oncology- Fort Worth, Fort Worth, Texas, United States
🇨🇦
British Columbia Cancer Agency, Vancouver, British Columbia, Canada
🇺🇸
Virginia Cancer Specialists, P.C., Fairfax, Virginia, United States

and more 19 locations

PD0332991/Paclitaxel in Advanced Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: PD0332991
Drug: Paclitaxel

First Posted Date: 2011-03-22

Last Posted Date: 2020-04-08

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 28

Registration Number: NCT01320592

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy